TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10793605

Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline 1 ml
Number of subjects: 64
Study: 8859174

Group type: EXPERIMENTAL
Intervention: Regional infusion chemotherapy with FUDR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study: 1534472

Group type: EXPERIMENTAL
Intervention: Doxacurium (5, 10, 15, or 20 micrograms/kg IV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Doxacurium (30 micrograms/kg IV)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neostigmine (5, 10, 20, or 40 micrograms/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neostigmine (to obtain 70% train-of-four recovery after 10 min)
Number of subjects: 48
Study: 2983461

Group type: EXPERIMENTAL
Intervention: oral acyclovir 200 mg X 4 daily for 28 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: oral acyclovir (after interruption of placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: oral acyclovir and placebo
Number of subjects: 35
Study: 31664468

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 100-150 mg/kg/min
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane ≤ 1 MAC
Number of subjects: 90
Study: 29521134

Group type: EXPERIMENTAL
Intervention: Tylerdipine hydrochloride (5, 15, 20, 25, and 30 mg)
Number of subjects: 127
Study: 30514716

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meniscectomy
Number of subjects: 0
Study: 26574928

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with fixed appliance for 6 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group awaiting treatment
Number of subjects: 120
Study: 25183688

Group type: EXPERIMENTAL
Intervention: Probiotic L. plantarum IS-10506 (10(10)CFU/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of probiotic L. plantarum IS-10506 (10(10)CFU/day) and zinc (8mg elemental zinc)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22464088

Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing training program (DBTP)
Number of subjects: 30
Study: 20482515

Group type: EXPERIMENTAL
Intervention: Oral naltrexone, 50 mg
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Intramuscular naltrexone (active for one month)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Oral naltrexone
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Oral naltrexone, higher doses
Number of subjects: 4000
Study: 18025916

Group type: EXPERIMENTAL
Intervention: Telephone problem-solving counseling by baccalaureate nurses
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study: 15228129

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin 1% topical gel (BP/C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study: 12568205

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enalapril 10 mg daily after washout
Number of subjects: 30
Study: 9525448

Group type: EXPERIMENTAL
Intervention: Topical steroids (200 microg fluticasone propionate twice daily; n = 16)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Matched placebo nasal spray (n = 17)
Number of subjects: 33
Study: 8580622

Group type: EXPERIMENTAL
Intervention: IgA antibodies to BSA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IgG antibodies to BSA
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IgA antibodies to ovalbumin
Number of subjects: 104

Group type: COMPARATOR
Intervention: IgG antibodies to ovalbumin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IgA antibodies to beta-lactoglobulin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IgA antibodies to cow's milk
Number of subjects: 104
Study: 2569364

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine
Number of subjects: 60
Study: 138578

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 mug to 80 mug
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 mug
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31248548

Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus Aspirin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1000
Study: 30168004

Group type: EXPERIMENTAL
Intervention: Evocalcet 1-20 mg (single dose)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Evocalcet 6 and 12 mg (multiple doses)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Evocalcet up to 12 mg (multiple doses)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Evocalcet up to 20 mg (single dose)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Evocalcet (compared to cinacalcet)
Number of subjects: 66
Study: 26657820

Group type: EXPERIMENTAL
Intervention: Standard + Therapeutic Education System (TES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 160
Study: 24560135

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 267 mg daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg daily
Number of subjects: 13
Study: 23177751

Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Perceptual judgments of voice qualities
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acoustic measures
Number of subjects: 42
Study: 20636275

Group type: EXPERIMENTAL
Intervention: SQV/ritonavir (SQV/r) 1000 mg/ritonavir 100 mg BID
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (habitual treatment)
Number of subjects: 28
Study: 17443204

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 16321761

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Radiotherapy and temozolomide
Number of subjects: 573
Study: 12696650

Group type: EXPERIMENTAL
Intervention: Automobile mechanics (exposed to automotive pollution)
Number of subjects: 29
Study: 10638488

Group type: EXPERIMENTAL
Intervention: Caracemide (11 patients)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Homoharringtonine (13 patients)
Number of subjects: 24
Study: 7595738

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (IFN‐alpha 2a) 20 x 10(6) U/m2 administered three times each week for 12 weeks
Number of subjects: 262

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (IFN‐alpha 2a)
Number of subjects: 262
Study: 2147842

Group type: EXPERIMENTAL
Intervention: Enoximone (total dose of 1.5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium nitroprussiate (3 micrograms/kg/mn)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All three drugs (Enoximone, Dobutamine, Sodium nitroprussiate)
Number of subjects: 10
Study: 7247053

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (21 calories/gm nitrogen)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypercaloric diet (138 calories/gm nitrogen)
Number of subjects: 40
Study: 31027300

Group type: EXPERIMENTAL
Intervention: High fiber cereal (90 g, 11 g fiber/90 g) consumed at Sohor for 20 consecutive days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Habitual diet intake (control group)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: High fiber cereal (90 g, 11 g fiber/90 g)
Number of subjects: 81
Study: 27809609

Group type: EXPERIMENTAL
Intervention: Investigational Device
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Device: FDA‐cleared syringe driver with FDA‐cleared infusion set
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Device: FDA‐cleared syringe driver attached to investigational device
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All devices (Investigational and Control)
Number of subjects: 21
Study: 25432497

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer
Number of subjects: 0
Study: 25016139

Group type: EXPERIMENTAL
Intervention: Three-unit posterior metal-ceramic FDP (Au-Pd-Ag alloy and InLine POM)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ceramic-ceramic FDP (ZirCAD and ZirPress)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both types of FDPs
Number of subjects: 89
Study: 22430709

Group type: EXPERIMENTAL
Intervention: Community Development Teams (CDT) approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard individualized implementation methods
Number of subjects: 0
Study: 21062616

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Triglyceride to high-density lipoprotein (TG:HDL) ratio
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 196
Study: 17619868

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (10 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine (10 mg)
Number of subjects: 38
Study: 15776301

Group type: EXPERIMENTAL
Intervention: Pringle maneuver (PR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: alpha‐GST concentrations (> 490 microg L(‐1))
Number of subjects: 75

Group type: COMPARATOR
Intervention: No intervention (NPR)
Number of subjects: 75
Study: 12081988

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT) with adjustment for postrandomization statin use
Number of subjects: 2763
Study: 9875580

Group type: EXPERIMENTAL
Intervention: ZDV-ddC
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: ZDV
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: ZDV-ddl
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: ddl
Number of subjects: 2467

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 2467
Study: 7840322

Group type: EXPERIMENTAL
Intervention: Fish oil supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger reference subjects (< 33 years old) taking no supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 2367600

Group type: EXPERIMENTAL
Intervention: Clomipramine (n = 6)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 17
Study: 6250106

Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiethylperazine
Number of subjects: 0
Study: 31652232

Group type: EXPERIMENTAL
Intervention: SELF‐FIT intervention
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (usual practices)
Number of subjects: 667
Study: 31735251

Group type: EXPERIMENTAL
Intervention: Rotations condition (n = 20)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Opposite directions condition (n = 20)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition (n = 17)
Number of subjects: 57
Study: 27631386

Group type: EXPERIMENTAL
Intervention: Intermittent Serial Casting (SC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (PT only)
Number of subjects: 51
Study: 25978742

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24229549

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Enhanced community standard
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 128
Study: 20825814

Group type: EXPERIMENTAL
Intervention: HIV rapid testing in the emergency department (ED)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nontargeted HIV screening
Number of subjects: 121

Group type: COMPARATOR
Intervention: Testing at nonpeak hours
Number of subjects: 121

Group type: COMPARATOR
Intervention: Diagnostic testing
Number of subjects: 121

Group type: COMPARATOR
Intervention: No testing or 'other'
Number of subjects: 121
Study: 19297309

Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome (CFS) patients
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome (CFS) patients and PBC group
Number of subjects: 205
Study: 17892996

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of mononuclear bone marrow cells (mBMCs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 16841333

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol (400 IU/day) and beta‐carotene (30 mg/day) supplements
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 540
Study: 12968238

Group type: EXPERIMENTAL
Intervention: Continuous intravenous administration of low‐dose fenoldopam (0.1‐0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional management (group A)
Number of subjects: 160
Study: 11013196

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 200
Study: 9042557

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 20
Study: 1623694

Group type: EXPERIMENTAL
Intervention: Niguldipine (0.3, 0.6, and 0.9 mg intravenously; 8 and 16 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (2 mg intravenously; 20 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6378555

Group type: EXPERIMENTAL
Intervention: Plastic wound ring drape (Opdrape, Triplus)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No plastic wound ring drape (control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups received preoperative systemic antibiotic prophylaxis
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Plastic wound ring drape
Number of subjects: 140
Study: 30990057

Group type: EXPERIMENTAL
Intervention: Psychological intervention group (IG) received a 90-minute session including psychoeducation, relaxation training, and coping skills.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG) did not receive any psychological intervention.
Number of subjects: 26
Study: 31093303

Group type: EXPERIMENTAL
Intervention: Acupuncture during paired-associative stimulation (PAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation techniques
Number of subjects: 0
Study: 29303212

Group type: EXPERIMENTAL
Intervention: Topical silicone gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Topical methylprednisolone cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study: 25884010

Group type: EXPERIMENTAL
Intervention: NP001 2 mg/kg
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: NP001 1 mg/kg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 23791499

Group type: EXPERIMENTAL
Intervention: Minimal Extracorporeal Circulation (MECC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional Cardiopulmonary Bypass (CPB)
Number of subjects: 120
Study: 21515889

Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 18837187

Group type: EXPERIMENTAL
Intervention: Testing for thrombophilia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16772623

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 15080830

Group type: EXPERIMENTAL
Intervention: Sublingual swallow immunotherapy (SLIT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 11399215

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Group cognitive-behavioral therapy
Number of subjects: 155
Study: 9429007

Group type: EXPERIMENTAL
Intervention: Homoeopathic medicine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 8484371

Group type: EXPERIMENTAL
Intervention: Occult blood testing for colorectal cancer screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3435119

Group type: EXPERIMENTAL
Intervention: Cefpimizole (100 mg to 2000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefotaxime and cephalothin (positive controls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefpimizole (500 mg and 1000 mg twice-daily)
Number of subjects: 0
Study: 29383525

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced (CE) cadaver-specific post-mortem computed tomography (PMCT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-enhanced (NE) cadaver-specific PMCT
Number of subjects: 132
Study: 27075708

Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy‐diabetes (BFST‐D) via telehealth
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional (Clinic) treatment
Number of subjects: 90
Study: 25127725

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (targeting systolic blood pressure < 120 mmHg)
Number of subjects: 3099

Group type: COMPARATOR
Intervention: Standard blood pressure control (targeting systolic blood pressure < 140 mmHg)
Number of subjects: 3099
Study: 24369254

Group type: EXPERIMENTAL
Intervention: INFα‐2b monotherapy (5×10(6), three times a week)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Combined therapy with entecavir (0.5 mg/day) plus adefovir (10 mg/day)
Number of subjects: 161
Study: 20704726

Group type: EXPERIMENTAL
Intervention: 6-month dietary and physical activity intervention including guidelines for vegetable and fruit intake, fat intake, fiber intake, alcohol consumption, and physical activity (30 minutes of brisk walking, 5 or more days per week).
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 6-month dietary and physical activity intervention.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 94
Study: 18391288

Group type: EXPERIMENTAL
Intervention: 3-D first person shooter (FPS) game training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 2-D non-FPS game training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Past experience with FPS games
Number of subjects: 22
Study: 16791523

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years program (PDFY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal contact control condition
Number of subjects: 0
Study: 14527092

Group type: EXPERIMENTAL
Intervention: Stepwise estimation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Simultaneous estimation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bootstrap validation
Number of subjects: 36
Study: 10920066

Group type: EXPERIMENTAL
Intervention: Vitamin E 300 mg/d
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vitamin E 600 mg/d
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vitamin E 1200 mg/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 8632687

Group type: EXPERIMENTAL
Intervention: Medical students, residents, and faculty attitudes toward decision-making input by older patients (75 years old)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Female respondents
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Residents
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Faculty
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Level of training
Number of subjects: 818
Study: 1283984

Group type: EXPERIMENTAL
Intervention: Carbimazole for 12 months (Group I, n = 28)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Carbimazole for 24 months (Group II, n = 24)
Number of subjects: 52
Study: 6531951

Group type: EXPERIMENTAL
Intervention: Single dose of trivalent influenza subunit vaccine (7 micrograms per dose)
Number of subjects: 88
Study: 30799237

Group type: EXPERIMENTAL
Intervention: Sebia FLC assay
Number of subjects: 177

Group type: COMPARATOR
Intervention: Freelite assay
Number of subjects: 177
Study: 30068502

Group type: EXPERIMENTAL
Intervention: e-Powered Parents (online program)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 146
Study: 27241710

Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg/carbidopa 25 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24286858

Group type: EXPERIMENTAL
Intervention: Adaptation to a swing phase perturbation on a treadmill
Number of subjects: 20
Study: 22156610

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA
Number of subjects: 115

Group type: COMPARATOR
Intervention: EBUS‐TBNCS
Number of subjects: 115
Study: 20345509

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 32
Study: 18544002

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg intravenously every 12 hours for 48 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dipyrone 2.5 g intravenously intraoperatively, followed by 1 g every 6 hours for 48 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cumulative piritramide administration
Number of subjects: 50
Study: 15669895

Group type: EXPERIMENTAL
Intervention: Citalopram or Paroxetine
Number of subjects: 119